Browsing ICR Divisions by author "Huddart, Robert"
Now showing items 21-40 of 118
-
Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic - Rapid Review.
Patel, K; Choudhury, A; Hoskin, P; Varughese, M; James, N; et al. (ELSEVIER SCIENCE LONDON, 2020-06-01)The current COVID-19 pandemic presents a substantial obstacle to cancer patient care. Data from China as well as risk models suppose that cancer patients, particularly those on active, immunosuppressive therapies are at ... -
Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer.
Huddart, R; Hafeez, S; Lewis, R; McNair, H; Syndikus, I; et al. (ELSEVIER SCIENCE INC, 2021-06-01)PURPOSE: Hypofractionated radiation therapy can be used to treat patients with muscle-invasive bladder cancer unable to have radical therapy. Toxicity is a key concern, but adaptive plan-of the day (POD) image-guided ... -
Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment.
Hafeez, S; McDonald, F; Lalondrelle, S; McNair, H; Warren-Oseni, K; et al. (ELSEVIER SCIENCE INC, 2017-05-01)PURPOSE AND OBJECTIVES: We report on the clinical outcomes of a phase 2 study assessing image guided hypofractionated weekly radiation therapy in bladder cancer patients unsuitable for radical treatment. METHODS AND ... -
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
Crabb, SJ; Martin, K; Abab, J; Ratcliffe, I; Thornton, R; et al. (ELSEVIER SCI LTD, 2017-12-01)BACKGROUND: Cisplatin is one of the most ototoxic chemotherapy drugs, resulting in a permanent and irreversible hearing loss in up to 50% of patients. Cisplatin and gentamicin are thought to damage hearing through a common ... -
Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy.
Pathmanathan, AU; McNair, HA; Schmidt, MA; Brand, DH; Delacroix, L; et al. (BRITISH INST RADIOLOGY, 2019-03-01)OBJECTIVE:: With increasing incorporation of MRI in radiotherapy, we investigate two MRI sequences for prostate delineation in radiographer-led image guidance. METHODS:: Five therapeutic radiographers contoured the prostate ... -
Controversies in the management of clinical stage 1 testis cancer.
Nason, GJ; Chung, P; Warde, P; Huddart, R; Albers, P; et al. (CANADIAN UROLOGICAL ASSOCIATION, 2020-11-01)<jats:p>In November 2018, The Canadian Testis Cancer Workshop was convened. The two-day workshop involved urologists, medical and radiation oncologists, pathologists, radiologists, physician’s assistants, residents and ... -
Correlation of Clinician- and Patient-Reported Outcomes in the BC2001 Trial.
Philipps, L; Porta, N; James, N; Huddart, R; Hafeez, S; et al. (ELSEVIER SCIENCE LONDON, 2023-05-01)AIMS: To evaluate whether there is sufficient correlation between patient-reported outcomes (PROs) and clinician-reported outcomes (CROs) in bladder cancer follow-up post-radiotherapy to streamline data collection and to ... -
Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
Kerns, SL; Fung, C; Monahan, PO; Ardeshir-Rouhani-Fard, S; Abu Zaid, MI; et al. (AMER SOC CLINICAL ONCOLOGY, 2018-05-20)Purpose In this multicenter study, we evaluated the cumulative burden of morbidity (CBM) among > 1,200 testicular cancer survivors and applied factor analysis to determine the co-occurrence of adverse health outcomes (AHOs). ... -
Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma.
Gilbert, DC; Al-Saadi, R; Thway, K; Chandler, I; Berney, D; et al. (AMER ASSOC CANCER RESEARCH, 2016-03-01)PURPOSE: Up to 50% of patients diagnosed with stage I nonseminomatous germ cell tumors (NSGCTs) harbor occult metastases. Patients are managed by surveillance with chemotherapy at relapse or adjuvant treatment up front. ... -
Differences in Quality of Life and Toxicity for Male and Female Patients following Chemo(radiotherapy) for Bladder Cancer.
Philipps, L; Porta, N; James, N; Huddart, R; Hafeez, S; et al. (ELSEVIER SCIENCE LONDON, 2023-02-01)AIMS: BC2001, a randomised trial of treatment for muscle-invasive bladder cancer, demonstrated no difference in health-related quality of life (HRQoL) or late toxicity between patients receiving radical radiotherapy with ... -
Diffusion-weighted MRI to determine response and long-term clinical outcomes in muscle-invasive bladder cancer following neoadjuvant chemotherapy.
Hafeez, S; Koh, M; Jones, K; Ghzal, AE; D'Arcy, J; et al. (FRONTIERS MEDIA SA, 2022-11-14)OBJECTIVE: This study aims to determine local treatment response and long-term survival outcomes in patients with localised muscle-invasive bladder cancer (MIBC) patients receiving neoadjuvant chemotherapy (NAC) using ... -
Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer.
Tree, AC; Jones, K; Hafeez, S; Sharabiani, MTA; Harrington, KJ; et al. (ELSEVIER SCIENCE INC, 2018-08-01)There is currently significant interest in the potential benefits of combining radiation and immune checkpoint blockade (ICB) to stimulate both regional and distant abscopal immune responses. In melanoma and lung cancer, ... -
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke, AO; Necchi, A; Park, SH; García-Donas, J; Huddart, RA; et al. (ELSEVIER SCIENCE INC, 2022-02-01)BACKGROUND: Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, was shown to be clinically active and tolerable in patients with advanced urothelial carcinoma and prespecified FGFR ... -
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Loriot, Y; Necchi, A; Park, SH; Garcia-Donas, J; Huddart, R; et al. (MASSACHUSETTS MEDICAL SOC, 2019-07-25)BACKGROUND: Alterations in the gene encoding fibroblast growth factor receptor (FGFR) are common in urothelial carcinoma and may be associated with lower sensitivity to immune interventions. Erdafitinib, a tyrosine kinase ... -
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
Dearnaley, DP; Jovic, G; Syndikus, I; Khoo, V; Cowan, RA; et al. (ELSEVIER SCIENCE INC, 2014-04-01)BACKGROUND: The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prostate cancer. Preliminary findings reported after 5 years of ... -
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.
Honecker, F; Aparicio, J; Berney, D; Beyer, J; Bokemeyer, C; et al. (OXFORD UNIV PRESS, 2018-08-01)The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held on 3-5 November 2016 in Paris, France. The conference included a multidisciplinary panel of 36 leading experts in the ... -
Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial.
Crabb, S; Wickens, R; Jane-Bibby, S; Dunkley, D; Lawrence, M; et al. (BMC, 2023-09-19)BACKGROUND: Bladder and urinary tract cancers account for approximately 21,000 new diagnoses and 5,000 deaths annually in the UK. Approximately 90% are transitional cell carcinomas where advanced disease is treated with ... -
Evaluation of non-vendor magnetic resonance imaging sequences for use in bladder cancer magnetic resonance image guided radiotherapy.
Chick, J; Alexander, S; Herbert, T; Huddart, R; Ingle, M; et al. (ELSEVIER, 2023-07-01)Hybrid systems that combine Magnetic Resonance Imaging (MRI) and linear accelerators are available clinically to guide and adapt radiotherapy. Vendor-approved MRI sequences are provided, however alternative sequences may ... -
Exploration of the treatment challenges in men with intellectual difficulties and testicular cancer as seen in Down syndrome: single centre experience.
Hafeez, S; Singhera, M; Huddart, R (BMC, 2015-06-26)Down syndrome is the most common chromosomal disorder in humans as well as the most common cause of inherited intellectual disability. A spectrum of physical and functional disability is associated with the syndrome as ... -
Failing to Close the Gap Between Evidence and Clinical Practice in Radical Bladder Cancer Radiotherapy.
Hafeez, S; Lewis, R; Griffin, C; Hall, E; Huddart, R (ELSEVIER SCIENCE LONDON, 2021-01-01)